~~<i id='694E831FB5'><strike id='694E831FB5'><tt id='694E831FB5'><pre id='694E831FB5'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：entertainment 2025-08-23 01:45:19 Page View：34

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'
Next article： Duchenne breakthrough therapy leaves behind pioneering families

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

1:45RandallMargraves,right,talkstoattorneyMickGrewal,ashepreparestostandinfrontofJudgeJaniceCunningh

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

FDA investigates CAR

TheFDAislookingintoadverseeventsinvolvinganumberofCAR-Ttherapies,includingBreyanzi.Illustration:STAT